Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults – Part 2: ulcerative colitis
Frontline Gastroenterology review of BSG… · 2025 · United Kingdom
Source and licence
- Authors
- Thomas D Butler, Jonathan P Segal
- Title
- Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults – Part 2: ulcerative colitis
- Journal
- Frontline gastroenterology, 2025
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC7619135
Licence statement of the original publication
This work is licensed under a CC BY 4.0 International license.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
This guideline review summarises the key recommendations for the diagnosis and management of ulcerative colitis from the updated 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults.
Contents of the original publication
The section headings of the original.
- Introduction
- Methodology
- Diagnosis of ulcerative colitis
- Monitoring in ulcerative colitis
- Management of ulcerative colitis
- Mild to moderate ulcerative colitis
- Moderate to severe ulcerative colitis
- Adalimumab is not suggested for the induction and maintenance of remission in patients with moderate to severe ulcerative colitis
- Other therapeutic strategies in ulcerative colitis
- Acute severe ulcerative colitis
- Proctitis
- Pouchitis
- Pregnancy in IBD
- Future directions
- Conclusions
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint